Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1247
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 973–984 of 1,247 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Results available

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

NCT03964727
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Solid Tumor
Interventions
Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
31
States / cities
Anchorage, Alaska • Glendale, Arizona • Goodyear, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Recruiting Not applicable Interventional

SELUTION4BTK Trial

NCT05055297
Status at this site: Recruiting
View directory record Official record
Conditions
Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
Interventions
SELUTION SLR™ DEB 014, Plain (Uncoated) Balloon Angioplasty (PTA)
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
30
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Active, not recruiting Phase 1 Interventional

DS-3201b in Participants With Lymphomas

NCT02732275
Site status not listed — check the official record
View directory record Official record
Conditions
Lymphoma, Malignant, Non-hodgkin Lymphoma
Interventions
DS-3201b
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
10
States / cities
Duarte, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT05729568
Site status not listed — check the official record
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stress and Pain in People Living With HIV

NCT06784908
Status at this site: Recruiting
View directory record Official record
Conditions
HIV, Depression, Cannabis Use Disorder, Stress, Pain
Interventions
Yale Pain Stress Task (YPST)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 68 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Recruiting Phase 1 Interventional

QTX3034 in Patients With KRAS G12D Mutation

NCT06227377
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors
Interventions
QTX3034, Cetuximab
Drug · Combination Product
Lead sponsor
Quanta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

NCT00775476
Site status not listed — check the official record
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Standard Adjuvant Endocrine Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
162
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

NCT06303921
Status at this site: Recruiting
View directory record Official record
Conditions
Tauopathies
Interventions
11C-M503 PET, Brain MRI, Amyloid PET, Neurological assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

NCT06864169
Site status not listed — check the official record
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Raludotatug Deruxtecan (R-DXd)
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Miami Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
Status at this site: Recruiting
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 8:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

NCT05428969
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Interventions
Bexmarilimab, Azacitidine, Venetoclax
Drug
Lead sponsor
Faron Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • New Haven, Connecticut • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 8:35 AM EDT

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.